MUMBAI, India, July 11 -- Intellectual Property India has published a patent application (202521007693 A) filed by Ms Parwati Chouhan; Mr. Shivpal Rewapati; Ms. Sonu Dwivedi; Ms. Tilottama Bhattacharya; Dr. Amit Modi; Ms. Preeti Maan Dr. Praveen Sharma; Dr. Neha Sharma; Dr. Tamalika Chakraborty; and Ms. Mukesh Rani, Raipur, Chhattisgarh, on Jan. 30, for 'novel composition of rosiglitazone and myo-inositol for managing pcod and insulin resistance.'
Inventor(s) include Ms Parwati Chouhan; Mr. Shivpal Rewapati; Ms. Sonu Dwivedi; Ms. Tilottama Bhattacharya; Dr. Amit Modi; Ms. Preeti Maan Dr. Praveen Sharma; Dr. Neha Sharma; Dr. Tamalika Chakraborty; and Ms. Mukesh Rani.
The application for the patent was published on July 11, under issue no. 28/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a novel pharmaceutical composition combining rosiglitazone (4 mg) and myo-inositol (2 g) for the management of polycystic ovary syndrome (PCOS) and insulin resistance. Rosiglitazone improves insulin sensitivity, addressing the metabolic issues in PCOS, while myo-inositol supports ovarian function and insulin signaling, targeting the reproductive dysfunctions associated with the condition. The formulation is designed as a reconstituted suspension, ensuring ease of administration, particularly for individuals who have difficulty swallowing tablets. The suspension is stable, with a viscosity optimized for patient comfort, and includes excipients like sucrose for improved taste and xanthan gum for consistency. This composition offers a holistic therapeutic solution, effectively addressing both the metabolic and reproductive challenges of PCOS, improving patient compliance and overall treatment outcomes."
Disclaimer: Curated by HT Syndication.
